Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$2 Mln
P/E Ratio
--
P/B Ratio
1.78
Industry P/E
--
Debt to Equity
--
ROE
-2.36 %
ROCE
-236.06 %
Div. Yield
0 %
Book Value
0.21
EPS
-1.17
CFO
$-15.47 Mln
EBITDA
$-24.32 Mln
Net Profit
$-27.27 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Protagenic Therapeutics (PTIX)
| -57.35 | -18.30 | -52.39 | -83.80 | -60.79 | -47.00 | -43.39 |
|
BSE Sensex*
| 1.87 | 3.65 | 5.11 | 9.06 | 11.24 | 21.08 | 11.16 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
Protagenic Therapeutics (PTIX)
| -50.22 | -38.13 | -71.12 | 31.90 | -25.54 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 35.59 | 9,973.38 | 20.56 | 23.13 | |
| 288.99 | 8,956.07 | 23.48 | 58.42 | |
| 25.13 | 9,559.25 | -- | -28.77 | |
| 100.68 | 10,030.35 | 30.81 | 14.16 |
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin... carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York. Address: 149 Fifth Avenue, New York, NY, United States, 10010 Read more
Co-Founder & Executive Chairman of the Board
Dr. Garo H. Armen Ph.D.
Co-Founder & Executive Chairman of the Board
Dr. Garo H. Armen Ph.D.
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Protagenic Therapeutics (PTIX) stood at $ 2 Mln as on 31-Dec-24
The share price of Protagenic Therapeutics (PTIX) is $0.21 (NASDAQ) as of 21-Apr-2025 16:00 EDT. Protagenic Therapeutics (PTIX) has given a return of -60.79% in the last 3 years.
Protagenic Therapeutics (PTIX) has a market capitalisation of $ 2 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Protagenic Therapeutics (PTIX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Protagenic Therapeutics (PTIX) and enter the required number of quantities and click on buy to purchase the shares of Protagenic Therapeutics (PTIX).
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York. Address: 149 Fifth Avenue, New York, NY, United States, 10010
The CEO & director of Dr. Garo H. Armen Ph.D.. is Protagenic Therapeutics (PTIX), and CFO & Sr. VP is Dr. Garo H. Armen Ph.D..
There is no promoter pledging in Protagenic Therapeutics (PTIX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Protagenic Therapeutics (PTIX) | Ratios |
|---|---|
|
Return on equity(%)
|
-236.06
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Protagenic Therapeutics (PTIX) was $0 Mln.
$-0.03
(
